Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 76.91M P/E - EPS this Y -7.50% Ern Qtrly Grth -
Income -40.88M Forward P/E -1.24 EPS next Y -4.00% 50D Avg Chg 10.00%
Sales 665k PEG - EPS past 5Y - 200D Avg Chg 8.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -48.00%
Recommedations 1.80 Quick Ratio 4.85 Shares Outstanding 46.55M 52W Low Chg 42.00%
Insider Own 7.25% ROA -34.12% Shares Float 43.17M Beta 1.95
Inst Own 28.65% ROE -58.80% Shares Shorted/Prior 6.90M/6.72M Price 1.71
Gross Margin - Profit Margin - Avg. Volume 154,138 Target Price 9.67
Oper. Margin -7,696.32% Earnings Date Oct 31 Volume 204,678 Change -7.57%
About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cardiff Oncology, Inc. News
11/19/24 Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
11/09/24 Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations
11/07/24 Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
10/30/24 Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
10/24/24 3 US Penny Stocks With Market Caps Over $40M
08/08/24 Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08/01/24 Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
07/24/24 Companies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In Growth
05/29/24 Cardiff Oncology to Present at the Jefferies Healthcare Conference
05/13/24 Cardiff Oncology to Present at Upcoming Investor Conferences in May
05/04/24 Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
05/02/24 Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
04/25/24 Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
04/08/24 Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
03/06/24 Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
03/03/24 Cardiff Oncology Full Year 2023 Earnings: Beats Expectations
03/01/24 Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results
02/29/24 Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
02/29/24 Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
02/29/24 Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
CRDF Chatroom

User Image Bullswin101 Posted - 7 hours ago

$CRDF added few thousand more shares @ 2.50 and it drops end of day. Not even sweating it though, this will be new SOC and definitely worth many multiples of my average. The lump of coal we've held through past Xmas days just needed a little more time and pressure from the market to deliver a precious gem this coming Xmas and beyond. CONFIDENTLY BULLISH!!!

User Image Slowroast1 Posted - 9 hours ago

$CRDF i will be in for 20k shares more at 1.94 if my 2.50 puts get assigned on or before Dec 20. If not I keep the 11k premium and will buy more at market on or before 🀷 either way is fine with me!

User Image mankind1 Posted - 9 hours ago

$CRDF loading up. Worth it at these prices

User Image RedneckHeathen2 Posted - 9 hours ago

$CRDF Watch them do it on the last day in December!

User Image UseSoap Posted - 11 hours ago

$CRDF news in 5 weeks max. now is loading zone if you want in. 🀩

User Image Llain1 Posted - 13 hours ago

$CRDF 550 more away we go

User Image mark31 Posted - 15 hours ago

$CRDF

User Image mark31 Posted - 15 hours ago

$CRDF we have blackrock in with us and look at the contract at the 5 strike

User Image mark31 Posted - 15 hours ago

$CRDF added some at 2.5 news due out by years end

User Image neba1 Posted - 16 hours ago

$CRDF "markets can remain irrational longer than you can remain solvent" John Maynard Keynes.

User Image biohuntress Posted - 1 day ago

$CRDF just thoughts... 6 arms of 15 pts each....2 soc/4 with Onva....are they frontloading the Onva pts to get the N up?...the 30 SOC pts for comparison are easy to recruit ....since they already know the "historical" SOC data the Onva data can be compared to that in real time....also 1 chemo arm could be more effective than the other...so there are a lot of scenarios ....data from 5 or 6 pts in each arm would be 20-24 Onva pts...we need as much Onva data as possible to move this....when Erlander said data and scans on the first 40 pts did he mean just Onva pts? https://cardiffoncology.com/wp-content/uploads/2024/11/2024-11-07_14-04-48-1.png

User Image mankind1 Posted - 1 day ago

$CRDF load up

User Image Alita300 Posted - 1 day ago

$CRDF this is getting ready to explode one way or the other. Don’t think there is middle ground anymore. It will either be great or not

User Image bschenck Posted - 1 day ago

$CRDF added some more. Data is all that matters but patent pr also points bullish for me too.

User Image Cutlass Posted - 1 day ago

$CRDF Always dips off the bell...good time to pick up a few under 2.50 πŸ“‹πŸ”Ž

User Image lonedaddy Posted - 1 day ago

$CRDF It will be interesting to see how the new administration cuts the corruption out of the FDA. Assuming Ovan Data is good this should be a candidate for new kind of life changing/saving drug that gets conditionally approved for use as the efficacy is good. That corrupt FDA approved COVID vax which did very little while this could be huge.

User Image richapd Posted - 1 day ago

$CRDF The onv patent for 1L Ras+ CRC lasts until 2023. Likely, its revenue will be at least equal to Avastin which has been $4-5B/y for the past 20years(until biosimilars came out last few years). And likely onv will find a home with other cancers not touched by Avastin(HR+Breast, Prostate, lymphoma, leukemia, pancreas,...). What kind of revenue will it bring? Only liability is data and approval, but certainly one may conjure as it would seem Erlanger is doing.

User Image LIT_L7 Posted - 1 day ago

$CRDF As we wait, I have been reading, searching, who is the competition... to see if CRDF is legit and does have the potential to Ace the trial and help patients besides being profitable for shareholders at this time. Corporate presentation does a good job explaining the science and drug efficacy. Delay in Results- some can be explained by the switch from 2nd. to 1st. patient pool and trial parameters being reset. The date has been moved out from mid 2024, 3rd. quarter, end of 2024... Reasons? One- patients are responding to the combo in 1st. line and the longer CRDF extends the timeline, the data gets better and better? Possible. Maybe the printers broke and trying to get parts to print the findings? Nah. Pfizer bought 2.4 million shares at $6.22 a share. So they had seen value at that price point. One note is by being in Ignite and the stock purchase they were able to place people on a newly formed science board and besides are first in line to see the data. On and on...Cheers-

User Image EASTCOASTROASTBEEF1977 Posted - 2 days ago

$CRDF Full disclosure … I only need 5$ a share. πŸ‘ so let’s get to it. Shall we.

User Image Vandenberg23 Posted - 2 days ago

$CRDF https://www.linkedin.com/posts/cardiffoncology_colorectalcancer-cancer-activity-7265141727311630336-Xfca?utm_medium=ios_app&utm_source=social_share_video_v2&utm_campaign=copy_link People that think this company gets sold for $45/share will never be able to reconcile that thought with the statement Mark made on LinkedIn

User Image EASTCOASTROASTBEEF1977 Posted - 2 days ago

$CRDF πŸ₯‚ pr is always nice. Thanks for posting. πŸ’ͺπŸ˜ŽπŸ‡ΊπŸ‡Έ

User Image Oknrv Posted - 2 days ago

$CRDF

User Image EASTCOASTROASTBEEF1977 Posted - 2 days ago

$QUBT Folks start thinking about the next sector getting hot. πŸ’ͺπŸ˜ŽπŸ‡ΊπŸ‡Έ $CRDF

User Image RedneckHeathen2 Posted - 2 days ago

$CRDF Curious.... I put in some buy orders on E*TRADE and they would reset on this ticker. They eventually allowed me to buy. Have any of you run into this?

User Image Cutlass Posted - 2 days ago

$CRDF Low volume shake πŸ’Ž

User Image EASTCOASTROASTBEEF1977 Posted - 2 days ago

@gregt8262 I moved over to $CRDF after buying in here a week ago. Not pumping but thinking sectors change soon and I like getting in low before the move.

User Image Cutlass Posted - 2 days ago

$CRDF πŸ‘‡

User Image EASTCOASTROASTBEEF1977 Posted - 2 days ago

$QUBT took my earnings and bought the low at $CRDF πŸ’ͺπŸ˜ŽπŸ‡ΊπŸ‡Έ my next big fight.

User Image Cutlass Posted - 2 days ago

$CRDF Add 🀠

User Image EASTCOASTROASTBEEF1977 Posted - 2 days ago

$CRDF I was wondering when peeps would catch that one. Thought about it after I posted. 🀣

Analyst Ratings
Craig-Hallum Buy Sep 6, 24
HC Wainwright & Co. Buy May 6, 24
HC Wainwright & Co. Buy Mar 6, 24
Piper Sandler Overweight Mar 1, 24
HC Wainwright & Co. Buy Aug 11, 23
HC Wainwright & Co. Buy Aug 8, 23
HC Wainwright & Co. Buy May 9, 23
HC Wainwright & Co. Buy Mar 29, 23
HC Wainwright & Co. Buy Mar 7, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PACE GARY W Director Director Dec 19 Buy 1.37 30,000 41,100 697,761 12/19/23
Erlander Mark Chief Executive Offi.. Chief Executive Officer Nov 25 Buy 1.43 10,000 14,300 24,481 11/29/22
White Lale Director Director Sep 19 Buy 1.635 15,000 24,525 113,788 09/20/22
TANNENBAUM RENEE P Director Director Sep 15 Buy 1.72 10,000 17,200 10,000 09/19/22
PACE GARY W Director Director Sep 15 Buy 1.71 150,000 256,500 644,811 09/19/22
Levine James E. Chief Financial Offi.. Chief Financial Officer Sep 16 Buy 1.557 30,000 46,710 60,000 09/19/22
Levine James E. Chief Financial Offi.. Chief Financial Officer Sep 13 Buy 6.48 30,000 194,400 30,000 09/13/21
Kelemen Vicki Exec. VP and COO Exec. VP and COO Nov 25 Option 2.48 35,321 87,596 40,375 11/25/20
Kelemen Vicki Exec. VP and COO Exec. VP and COO Nov 25 Sell 18.6 35,321 656,971 5,054 11/25/20